BioCatalystWatch
ELVNWorkspace / ELVN / OverviewCompany library
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. (ELVN)

Website

Featured programme · tovinontrine (IMR-687)

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

Relcobatinib

BCR::ABL1

PreINDP1P2FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Relcobatinib

BCR::ABL1

PreINDP1P2FilingApproved
Upcoming / outlook

Other pipelines

Relcobatinib

BCR::ABL1

PreINDP1P2P3FilingApproved
Relcobatinib

BCR::ABL1

PreINDP1P2P3FilingApproved
ELV-3111

pan-RAF × BRAF

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ELVN PR & News

PR & News

ELVN SEC archive